Skip to main content

Philips Avent turns to technology from Zoundream

| News

Philips Avent turns to technology from Zoundream

22.10.2024

Artificial Intelligence from the Basel-based company Zoundream has been integrated into the latest generation of a baby monitor developed by Philips Avent. Zoundream’s infant voice analysis offers parents real-time insights into their baby’s needs, in addition to supporting the early detection of pathologies.

Zoundream's cry translation technology is now integrated into Philips Avent’s Premium Connected Baby Monitors (image taken from Zoundream website)

Zoundream is celebrating another market launch: the Zoundream technology for infant cry translation has been integrated in the latest Premium Connected Baby Monitor developed by Philips Avent. The combination of Philips Avent’s global leadership in baby care with Zoundream’s expertise in the areas of Artificial Intelligence (AI) and infant voice analysis serves to strengthen Zoundream’s presence in the industry, as the Basel-based startup writes in a press release.

This voice recognition technology interprets different types of crying. Through continuous monitoring, it gives parents real-time insights into their baby’s emotional state and needs, in addition to helping them to respond more quickly and accurately. This ultimately opens up a new dimension of understanding for early-stage parenting.

Zoundream is part of the DayOne portfolio

In September 2023, Zoundream reported a first major market launch. This involved the Maxi Cosi See Pro Baby Monitor from Dorel Juvenile, which was the first product anywhere in the world to integrate Zoundream’s cry analysis technology.

In July 2024, Zoundream completed a takeover of Babbly. The AI technology developed by the Canadian startup is focused on the early detection of speech and language development disorders in infants. With this technological extension, Zoundream is seeking to become the global market leader for infant voice analysis.

In 2019, the year in which Zoundream was founded, the startup, which is based at the Novartis Campus site of the Switzerland Innovation Park Basel Area, received support from the investment and innovation promotion agency Basel Area Business & Innovation and took part in its DayOne Accelerator.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.